STOCKHOLM May 25 Swedish medical technology
firm Getinge said on Sunday it would postpone its
planned update to investors on May 27 due to discussions with
the United States Food and Drug Administration.
The medical technology group issued its third profit warning
in just over a year in March as it said it faced more than a
year of heavy spending to improve controls following inspections
by the U.S. FDA last year.
"Getinge Group will hold its capital markets day when it has
more to report about these discussions, their potential
financial impact on the company and the latest progress being
made in strengthening Medical Systems' quality management
systems," the company said in a statement.
Getinge repeated that improvements in the Medical Systems
unit were expected to be completed in the second half of 2015
and costs expected to amount to around 800 million Swedish
crowns, which was charged to the first quarter results this
In March, the company said it was reviewing controls at all
manufacturing units within Medical Systems, which accounts for
roughly half of group sales, and that consultants brought in to
address the issues would cost about 125 million crowns per
quarter for a period of six to seven quarters.
(Reporting by Simon Johnson; Editing by Alison Williams)